Evaluation of In Vitro Inhibition of β-Hematin Formation: A Step Towards a Comprehensive Understanding of the Mechanism of Action of New Arylamino Alcohols
Microorganisms · 07.12.2024 · 12 (12) · 2524
DOI: 10.3390/microorganisms12122524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 07.12.2024. Verfasst von Céline Damiani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Agents Infectieux, Résistance et Chimiothérapie (AGIR), UR 4294, Université de Picardie Jules Verne, 1 rue des Louvels, 80037 Amiens, France. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, DGA (Direction Générale de l’Armement, Ministère de la Défense, France).
Abstract (Originalsprache)
Currently, artemisinin-based combination therapy is recommended as first-line treatment of uncomplicated falciparum malaria. Arylamino alcohols (AAAs) such as mefloquine (MQ) are the preferred partner drugs due to their longer half-life, reliable absorption and strong antimalarial activity. However, the mode of action of MQ remains poorly understood and its neurotoxicity limits its use. Furthermore, the emergence of drug-resistant parasites requires development of new antimalarial drugs. The aim of this study was to evaluate the β-hematin inhibition capacity of three pairs of enantiopure AAAs 1–3 (a/S and b/R) derived from MQ or enpiroline (ENP), a pyridine-based MQ analog with strong antimalarial activity. Inhibition of β-hematin—the synthetic counterpart of hemozoin formation—was determined for each compound. Antimalarial activity against W2 and 3D7 Plasmodium falciparum strains as well as percentages of inhibition of β-hematin formation were compared to those of reference molecules, i.e., chloroquine (CQ), MQ and ENP. Furthermore, a cytotoxicity study on the human-derived hepatocarcinoma cell line HepG2 was performed. With high antimalarial activity, stronger ability to inhibit β-hematin formation and low cytotoxicity, AAAs 1a-b and 2a are the most promising. These findings provide a better understanding of their potential mechanisms of action and may pave the way toward developing new lead compounds.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Agents Infectieux, Résistance et Chimiothérapie (AGIR), UR 4294, Université de Picardie Jules Verne, 1 rue des Louvels, 80037 Amiens, France.
- Laboratoire de Parasitologie et Mycologie, Centre de Biologie Humaine, CHU Amiens-Picardie, 1 Rond-Point du Pr Cabrol, 80054 Amiens, France.
ORCID-Profile: Céline Damiani, Yohann Le Govic, Anne Totet, Alexandra Dassonville-Klimpt, Pascal Sonnet
Förderung
- Agence Nationale de la Recherche
- DGA (Direction Générale de l’Armement, Ministère de la Défense, France)
Zitieren
APA
Damiani, C., Soler, F., Le Govic, Y., Totet, A., Bentzinger, G., Bouchut, A., Mustière, R., Agnamey, P., Dassonville-Klimpt, A., & Sonnet, P. (2024). Evaluation of In Vitro Inhibition of β-Hematin Formation: A Step Towards a Comprehensive Understanding of the Mechanism of Action of New Arylamino Alcohols. Microorganisms, 12(12), 2524. https://doi.org/10.3390/microorganisms12122524
Vancouver
Damiani C, Soler F, Le Govic Y, Totet A, Bentzinger G, Bouchut A, et al. Evaluation of In Vitro Inhibition of β-Hematin Formation: A Step Towards a Comprehensive Understanding of the Mechanism of Action of New Arylamino Alcohols. Microorganisms. 2024;12(12):2524. doi:10.3390/microorganisms12122524
BibTeX
@article{Damiani2024,
author = {Damiani, Céline and Soler, Floriane and Le Govic, Yohann and Totet, Anne and Bentzinger, Guillaume and Bouchut, Anne and Mustière, Romain and Agnamey, Patrice and Dassonville-Klimpt, Alexandra and Sonnet, Pascal},
title = {Evaluation of In Vitro Inhibition of β-Hematin Formation: A Step Towards a Comprehensive Understanding of the Mechanism of Action of New Arylamino Alcohols},
journal = {Microorganisms},
year = {2024},
volume = {12},
number = {12},
pages = {2524},
doi = {10.3390/microorganisms12122524}
}
EUVIMED